RECURSION PHARMACEUTICALS, INC.
Company Stats
- Market Cap
- $2.2B
- as of Sep 30, 2026
- Shares Outstanding
- 540.6M
- Free Float
- 93.2%
Income Statement
- Revenue
- $74.7M
- Operating Income
- -$648.1M
- Net Income
- -$644.8M
- EBITDA
- -$564.4M
- Revenue Growth, 3Y
- 23.3%
- FCF Margin, 3Y Avg
- -604.2%
- FCF Margin, Worst Year
- -672.4%
Cash Flow
- Free Cash Flow
- -$378.3M
- FCF Yield
- -16.9%
- Owner FCF Yield
- -21.9%
Balance Sheet
- Cash & Equivalents
- $743.3M
Returns & Capital
- SBC, 3Y Avg
- $82.1M
Cash Flow by Year
| Year | Revenue | FCF | Margin |
|---|---|---|---|
| FY2025 | $74.7M | -$378.3M | -506.5% |
| FY2024 | $58.8M | -$372.9M | -633.7% |
| FY2023 | $44.6M | -$299.7M | -672.4% |
| FY2022 | $39.8M | -$120.6M | -302.6% |
| FY2021 | $10.2M | -$198.4M | -1949.4% |
Annual filing data through FY ended December 31, 2025; shares and float as of November 1, 2026. Yields and enterprise value use the calculated market cap above, at its as-of date. Ratios are our calculations from reported figures.
Stronger demand supports expansion as pricing diverges
Healthcare Earnings: Demand Surges, Costs Bite Back